Tax-Related Insider Sales
Scholar Rock Directors Sell Stock for Tax Withholding Amid Analyst Price Target Boosts
Key Points
Burow's post-sale stake totaled 114,657 shares, valued at about $6.16 million after selling 3,053 shares on July 1.
Reed's post-sale stake totaled 19,518 shares, valued at about $1.05 million after selling 3,053 shares on July 1.
Analysts boosted price targets for Scholar Rock around the time of the trades: Wedbush raised to $58, HC Wainwright raised to $65, and JPMorgan increased its target to $50.
AQR Capital Management LLC boosted its SRRK holdings by 609.3% in the first quarter, now owning 57,294 shares worth about $1.84 million after purchasing the additional shares.
The insider transactions were conducted under a Rule 10b-5-1 trading plan adopted on March 31, 2026 to cover tax withholding related to vesting RSUs.
Four Scholar Rock Holding Corporation directors sold shares on July 1, each offloading stock to cover taxes tied to vesting equity awards. The sales ranged from 2,544 to 5,446 shares per director, at prices between $53.74 and $53.88, according to Watchlist News and Ticker Report.
The transactions were not discretionary bets against the company. Each sale was made under a Rule 10b-5-1 trading plan adopted March 31, 2026, a pre-set plan designed specifically to cover tax withholding on restricted stock units as they vest.
Who Sold What and for How Much
Director Katie Peng sold the most shares — 5,446 — at $53.88 each, worth roughly $293,000. That cut her stake by 13.70%. Kristina Burow and Joshua Reed each sold 3,053 shares. Burow's sale trimmed her holdings by 2.59%, leaving her with 114,657 shares worth about $6.16 million. Reed's sale cut his stake by 13.53%, leaving him with 19,518 shares worth about $1.05 million.
Michael Gilman sold 2,544 shares, the fewest of the four, at around $53.74 per share. His stake fell by 4.10%. All four filings were submitted to the SEC in the routine course of insider transaction reporting.
Stock Trading Near $55 as Analysts Lift Targets
Scholar Rock's stock was trading near $55.36 at the time of the sales. The company carries a market cap of about $6.63 billion and a beta of 0.67, meaning it moves less than the broader market. Its current ratio of 8.64 signals strong short-term liquidity.
Analyst sentiment has been positive. Wedbush raised its price target to $58. HC Wainwright went higher, lifting its target to $65. JPMorgan set its target at $50. All three moves came around the same period as the insider transactions, suggesting Wall Street still sees upside from current levels.
Q1 Earnings Miss and Full-Year Loss Expected
Scholar Rock reported Q1 results on May 7. Earnings per share came in at -$0.83, missing the consensus estimate by $0.01. Analysts project a full-year loss of -$3.23 per share for the current year. The company is in a spending phase typical of clinical-stage biotech firms.
Despite the losses, institutional interest is growing. AQR Capital Management boosted its Scholar Rock stake by 609.3% in the first quarter. It now owns 57,294 shares worth about $1.84 million. That kind of institutional buying often signals confidence in the company's long-term pipeline.
Why Tax-Related Insider Sales Are Routine
When company insiders receive restricted stock units, they owe income tax the moment those shares vest. To pay that bill without using outside cash, many executives and directors sell a portion of the newly vested shares. That is exactly what happened here. None of the four directors made open-market decisions to exit their positions.
The use of a Rule 10b-5-1 plan adds another layer of routine clarity. These plans are set up in advance, removing any question of trading on insider information. The plan here was adopted on March 31, 2026, well before the July 1 sale dates.
Sentiment
Mostly PositivePublishers
11
Articles
3
Reach
14
